EcoDrugPlus

Checkpoint Kinase 2

Ensembl ID : ENSDARG00000025820
Gene Symbol: CHEK2
25 Enzyme and pathways 5 Cross references
206 Possible Orthologues:

Chemokine (C-C Motif) Receptor 9a

Ensembl ID : ENSDARG00000055186
Gene Symbol: CCR9A
5 Cross references
190 Possible Orthologues:

Chemokine (C-C Motif) Receptor 9b

Ensembl ID : ENSDARG00000099738
Gene Symbol: CCR9B
5 Cross references
194 Possible Orthologues:

Chemokine (C-X-C Motif) Receptor 2

Ensembl ID : ENSDARG00000054975
Gene Symbol: CXCR2
11 Enzyme and pathways 5 Cross references
275 Possible Orthologues:

Chemokine (C-X-C Motif) Receptor 4a

Ensembl ID : ENSDARG00000057633
Gene Symbol: CXCR4A
11 Enzyme and pathways 5 Cross references
202 Possible Orthologues:

Chemokine (C-X-C Motif), Receptor 4b

Ensembl ID : ENSDARG00000041959
Gene Symbol: CXCR4B
5 Cross references
205 Possible Orthologues:

Cholecystokinin A Receptor

Ensembl ID : ENSDARG00000052089
Gene Symbol: CCKAR
7 Enzyme and pathways 6 Cross references
201 Possible Orthologues:

Cholecystokinin B Receptor

Ensembl ID : ENSDARG00000076824
Gene Symbol: CCKBR
7 Enzyme and pathways 6 Cross references
195 Possible Orthologues:

Cholesteryl Ester Transfer Protein, Plasma

Ensembl ID : ENSDARG00000030872
Gene Symbol: CETP
5 Enzyme and pathways 5 Cross references
151 Possible Orthologues:

Cholinergic Receptor, Muscarinic 1a

Ensembl ID : ENSDARG00000037292
Gene Symbol: CHRM1A
5 Cross references
104 Possible Orthologues:

Cholinergic Receptor, Muscarinic 2a

Ensembl ID : ENSDARG00000098612
Gene Symbol: CHRM2A
12 Enzyme and pathways 5 Cross references
196 Possible Orthologues:

Cholinergic Receptor, Muscarinic 2b

Ensembl ID : ENSDARG00000116374
Gene Symbol: CHRM2B
5 Cross references
185 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).